GILEAD SCIENCES SL
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
Completed
- Conditions
- Hepatitis C Virus Infection
- Interventions
- Drug: SOFDrug: COPE
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 552
- Registration Number
- NCT02537379
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen
- First Posted Date
- 2015-08-31
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 49
- Registration Number
- NCT02536313
- Locations
- 🇺🇸
The Texas Liver Institute, San Antonio, Texas, United States
Dose Optimization Study of Idelalisib in Follicular Lymphoma
- First Posted Date
- 2015-08-31
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 96
- Registration Number
- NCT02536300
- Locations
- 🇬🇧
Barts Health Trust, London, United Kingdom
🇨🇿Fakulni newmcince v Motole, Onkologicka klinika 2. LF UK a FN Motol, Praha 5, Czechia
🇦🇺Calvary Norht Adelaide Hosptial, Woodville South, South Australia, Australia
Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection
Phase 2
Completed
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-08-27
- Last Posted Date
- 2018-11-28
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 61
- Registration Number
- NCT02534350
Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol
Phase 1
Completed
- Conditions
- HCV Infection
- Interventions
- First Posted Date
- 2015-08-26
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 15
- Registration Number
- NCT02533427
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 56
- Registration Number
- NCT02521376
- Locations
- 🇺🇸
The Texas Liver Institute, San Antonio, Texas, United States
🇳🇿Auckland Clinical Studies, Auckland, New Zealand
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis
Phase 2
Terminated
- Conditions
- Ulcerative Colitis
- Interventions
- Biological: AndecaliximabBiological: Placebo
- First Posted Date
- 2015-08-11
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 165
- Registration Number
- NCT02520284
A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
Terminated
- Conditions
- Hepatitis C Virus Infection
- First Posted Date
- 2015-07-29
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 461
- Registration Number
- NCT02510300
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function
- First Posted Date
- 2015-07-28
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 52
- Registration Number
- NCT02509624
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 255
- Registration Number
- NCT02487030
© Copyright 2025. All Rights Reserved by MedPath